Get notified of page updates

Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)

Clinicaltrials.gov identifier:
NCT04191135

Study Contact Information:

For additional information, please contact:

Toll Free Number: 1-888-577-8839 or email: [email protected]

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Contact
Glossary on
off

About the Study

This study will look at how people with advanced () respond to different combinations of drugs. The study will look at two different treatment periods:

  • Initial period: during this initial study period, participants will receive a combination of chemotherapy and drugs. Participants with stable cancer or an improvement will be able to continue to the next part of the study.
  • Followup period: Continuing participants will be assigned to one of two groups. One group will receive the same drug combination during the followup period. The second group will instead  plus a type of known as a during the follow-up period.  

NOTE: This study is no longer enrolling patients. 

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is NOT Open To:

Study Contact Information:

For additional information, please contact:

Toll Free Number: 1-888-577-8839 or email: [email protected]

Clinicaltrials.gov identifier:
NCT04191135

Study Contact Information:

For additional information, please contact:

Toll Free Number: 1-888-577-8839 or email: [email protected]

PRINTER FRIENDLY PAGE